<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2018-07-12" updated="2019-12-02">
  <drugbank-id primary="true">DB14517</drugbank-id>
  <drugbank-id>DBSALT002422</drugbank-id>
  <name>Aluminium phosphate</name>
  <description/>
  <cas-number>7784-30-7</cas-number>
  <unii>F92V3S521O</unii>
  <average-mass>121.9529</average-mass>
  <monoisotopic-mass>121.934958441</monoisotopic-mass>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action>Aluminum Acetate is an astringent.  An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application.  The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied.  Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot. </mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of inorganic compounds known as post-transition metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is a post-transition metal.</description>
    <direct-parent>Post-transition metal phosphates</direct-parent>
    <kingdom>Inorganic compounds</kingdom>
    <superclass>Mixed metal/non-metal compounds</superclass>
    <class>Post-transition metal oxoanionic compounds</class>
    <subclass>Post-transition metal phosphates</subclass>
    <alternative-parent>Inorganic oxides</alternative-parent>
    <alternative-parent>Inorganic salts</alternative-parent>
    <alternative-parent>Post-transition metal salts</alternative-parent>
    <substituent>Inorganic oxide</substituent>
    <substituent>Inorganic post-transition metal salt</substituent>
    <substituent>Inorganic salt</substituent>
    <substituent>Post-transition metal phosphate</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Aluminum phosphate</synonym>
  </synonyms>
  <products>
    <product>
      <name>Gelfos</name>
      <labeller>Boryung Pharmaceutical Co., Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>64644-3001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-18</started-marketing-on>
      <ended-marketing-on>2016-12-12</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength>61.9 g/100g</strength>
      <route>Oral</route>
      <fda-application-number>part331</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gelfos M</name>
      <labeller>Boryung Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>64644-6001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on>2016-12-12</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part331</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gelfos M</name>
      <labeller>Boryung Pharmaceutical Co., Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>64644-5001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-28</started-marketing-on>
      <ended-marketing-on>2016-12-12</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part331</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gelfos M</name>
      <labeller>Boryung Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>64644-7001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on>2017-04-03</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part331</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gelfos M</name>
      <labeller>Boryung Pharmaceutical Co., Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>64644-4002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-28</started-marketing-on>
      <ended-marketing-on>2016-04-11</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength>61.9 g/100g</strength>
      <route>Oral</route>
      <fda-application-number>part331</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gelfos M</name>
      <labeller>Boryung Pharmaceutical Co., Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>64644-4001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-18</started-marketing-on>
      <ended-marketing-on>2016-12-12</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength>61.9 g/100g</strength>
      <route>Oral</route>
      <fda-application-number>part331</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gelfos-M</name>
      <labeller>I World Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>73442-0003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part331</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gelfos-M</name>
      <labeller>LYDIA Co., Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>72988-0017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part331</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gelfos-M</name>
      <labeller>OASIS TRADING</labeller>
      <ndc-id/>
      <ndc-product-code>72689-0008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part331</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gelfose</name>
      <labeller>Boryung Pharmaceutical Co., Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>64644-1001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-08</started-marketing-on>
      <ended-marketing-on>2016-12-12</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength>61.9 g/100g</strength>
      <route>Oral</route>
      <fda-application-number>part331</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gelfose M</name>
      <labeller>Boryung Pharmaceutical Co., Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>64644-2001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-08</started-marketing-on>
      <ended-marketing-on>2016-12-12</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength>61.9 g/100g</strength>
      <route>Oral</route>
      <fda-application-number>part331</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Gelfose</name>
      <ingredients>Aluminium phosphate</ingredients>
    </mixture>
    <mixture>
      <name>Gelfos</name>
      <ingredients>Aluminium phosphate</ingredients>
    </mixture>
    <mixture>
      <name>Gelfos M</name>
      <ingredients>Aluminium phosphate + Dimethicone + Magnesium hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Gelfose M</name>
      <ingredients>Aluminium phosphate</ingredients>
    </mixture>
    <mixture>
      <name>Gelfos M</name>
      <ingredients>Aluminium phosphate</ingredients>
    </mixture>
    <mixture>
      <name>Gelfos M</name>
      <ingredients>Aluminium phosphate</ingredients>
    </mixture>
    <mixture>
      <name>Gelfos M</name>
      <ingredients>Aluminium phosphate + Dimethicone + Magnesium hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Gelfos M</name>
      <ingredients>Aluminium phosphate + Dimethicone + Magnesium hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Gelfos-M</name>
      <ingredients>Aluminium phosphate + Dimethicone + Magnesium hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Gelfos-M</name>
      <ingredients>Aluminium phosphate + Dimethicone + Magnesium hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Gelfos-M</name>
      <ingredients>Aluminium phosphate + Dimethicone + Magnesium hydroxide</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids</category>
      <mesh-id>D000143</mesh-id>
    </category>
    <category>
      <category>Acids, Noncarboxylic</category>
      <mesh-id>D000148</mesh-id>
    </category>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Aluminium Compounds</category>
      <mesh-id>D017607</mesh-id>
    </category>
    <category>
      <category>Aluminum and magnesium containing antacids</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anions</category>
      <mesh-id>D000838</mesh-id>
    </category>
    <category>
      <category>Antacids</category>
      <mesh-id>D000863</mesh-id>
    </category>
    <category>
      <category>Drugs for Acid Related Disorders</category>
      <mesh-id/>
    </category>
    <category>
      <category>Electrolytes</category>
      <mesh-id>D004573</mesh-id>
    </category>
    <category>
      <category>Gastric Acid Lowering Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gastrointestinal Agents</category>
      <mesh-id>D005765</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Ions</category>
      <mesh-id>D007477</mesh-id>
    </category>
    <category>
      <category>Metal cations</category>
      <mesh-id>D002412</mesh-id>
    </category>
    <category>
      <category>Metal divalent cations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Phosphoric Acids</category>
      <mesh-id>D010756</mesh-id>
    </category>
    <category>
      <category>Phosphorus Acids</category>
      <mesh-id>D017976</mesh-id>
    </category>
    <category>
      <category>Phosphorus Compounds</category>
      <mesh-id>D017553</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Gel</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Oral</route>
      <strength>61.9 g/100g</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A02AB03">
      <level code="A02AB">Aluminium compounds</level>
      <level code="A02A">ANTACIDS</level>
      <level code="A02">DRUGS FOR ACID RELATED DISORDERS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01066</drugbank-id>
      <name>Cefditoren</name>
      <description>The serum concentration of Cefditoren can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00422</drugbank-id>
      <name>Methylphenidate</name>
      <description>Aluminium phosphate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08930</drugbank-id>
      <name>Dolutegravir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Dolutegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01344</drugbank-id>
      <name>Tolevamer</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09020</drugbank-id>
      <name>Bisacodyl</name>
      <description>The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ramipril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Trandolapril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Benazepril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Enalapril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Moexipril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Perindopril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Quinapril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Omapatrilat resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Rescinnamine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Cilazapril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Spirapril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Temocapril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Imidapril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13166</drugbank-id>
      <name>Zofenopril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Zofenopril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13312</drugbank-id>
      <name>Delapril</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Delapril resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14125</drugbank-id>
      <name>Benazeprilat</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Benazeprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14207</drugbank-id>
      <name>Fosinoprilat</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Fosinoprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14208</drugbank-id>
      <name>Ramiprilat</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ramiprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14209</drugbank-id>
      <name>Trandolaprilat</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Trandolaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14210</drugbank-id>
      <name>Moexiprilat</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Moexiprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14213</drugbank-id>
      <name>Perindoprilat</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Perindoprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14217</drugbank-id>
      <name>Quinaprilat</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Quinaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14231</drugbank-id>
      <name>Quinoline Yellow WS</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Quinoline Yellow WS resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01416</drugbank-id>
      <name>Cefpodoxime</name>
      <description>The serum concentration of Cefpodoxime can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>Aluminium phosphate may decrease the excretion rate of Quinidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>The therapeutic efficacy of Allopurinol can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Fexofenadine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06817</drugbank-id>
      <name>Raltegravir</name>
      <description>The serum concentration of Raltegravir can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01218</drugbank-id>
      <name>Halofantrine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01586</drugbank-id>
      <name>Ursodeoxycholic acid</name>
      <description>The serum concentration of Ursodeoxycholic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02123</drugbank-id>
      <name>Glycochenodeoxycholic Acid</name>
      <description>The serum concentration of Glycochenodeoxycholic Acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02659</drugbank-id>
      <name>Cholic Acid</name>
      <description>The serum concentration of Cholic Acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02691</drugbank-id>
      <name>Glycocholic acid</name>
      <description>The serum concentration of Glycocholic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03619</drugbank-id>
      <name>Deoxycholic acid</name>
      <description>The serum concentration of Deoxycholic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>The serum concentration of Taurocholic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05990</drugbank-id>
      <name>Obeticholic acid</name>
      <description>The serum concentration of Obeticholic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06777</drugbank-id>
      <name>Chenodeoxycholic acid</name>
      <description>The serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08833</drugbank-id>
      <name>Taurochenodeoxycholic acid</name>
      <description>The serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08834</drugbank-id>
      <name>Tauroursodeoxycholic acid</name>
      <description>The serum concentration of Tauroursodeoxycholic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08857</drugbank-id>
      <name>Bamet-UD2</name>
      <description>The serum concentration of Bamet-UD2 can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08858</drugbank-id>
      <name>cis-Diamminechlorocholylglycinateplatinum(II)</name>
      <description>The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11622</drugbank-id>
      <name>Dehydrocholic acid</name>
      <description>The serum concentration of Dehydrocholic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11789</drugbank-id>
      <name>Hyodeoxycholic Acid</name>
      <description>The serum concentration of Hyodeoxycholic Acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11860</drugbank-id>
      <name>Aramchol</name>
      <description>The serum concentration of Aramchol can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14016</drugbank-id>
      <name>Ox bile extract</name>
      <description>The serum concentration of Ox bile extract can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00847</drugbank-id>
      <name>Cysteamine</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01063</drugbank-id>
      <name>Acetophenazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Periciazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05687</drugbank-id>
      <name>BL-1020</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11540</drugbank-id>
      <name>Propiopromazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13213</drugbank-id>
      <name>Butaperazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Butaperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13382</drugbank-id>
      <name>Chlorproethazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13420</drugbank-id>
      <name>Thiazinam</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Dixyrazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06799</drugbank-id>
      <name>Methenamine</name>
      <description>The therapeutic efficacy of Methenamine can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00256</drugbank-id>
      <name>Lymecycline</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00453</drugbank-id>
      <name>Clomocycline</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00931</drugbank-id>
      <name>Metacycline</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Metacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12035</drugbank-id>
      <name>Sarecycline</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Sarecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Omadacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13092</drugbank-id>
      <name>Meclocycline</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Meclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13264</drugbank-id>
      <name>Penimepicycline</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Penimepicycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06824</drugbank-id>
      <name>Triethylenetetramine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic acid</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05488</drugbank-id>
      <name>Technetium Tc-99m ciprofloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11404</drugbank-id>
      <name>Enrofloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11443</drugbank-id>
      <name>Orbifloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11491</drugbank-id>
      <name>Sarafloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11511</drugbank-id>
      <name>Difloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13261</drugbank-id>
      <name>Sitafloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13772</drugbank-id>
      <name>Rufloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13823</drugbank-id>
      <name>Pipemidic acid</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>The serum concentration of Pamidronic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00399</drugbank-id>
      <name>Zoledronic acid</name>
      <description>The serum concentration of Zoledronic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00630</drugbank-id>
      <name>Alendronic acid</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The serum concentration of Ibandronate can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00720</drugbank-id>
      <name>Clodronic acid</name>
      <description>The serum concentration of Clodronic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00884</drugbank-id>
      <name>Risedronic acid</name>
      <description>The serum concentration of Risedronic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01077</drugbank-id>
      <name>Etidronic acid</name>
      <description>The serum concentration of Etidronic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>The serum concentration of Tiludronic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06255</drugbank-id>
      <name>Incadronic acid</name>
      <description>The serum concentration of Incadronic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The bioavailability of Betamethasone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The bioavailability of Fluticasone propionate can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The bioavailability of Triamcinolone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The bioavailability of Prednisone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The bioavailability of Fludrocortisone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The bioavailability of Hydrocortisone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The bioavailability of Prednisolone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The bioavailability of Methylprednisolone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The bioavailability of Trilostane can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The bioavailability of Budesonide can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The bioavailability of Cortisone acetate can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The bioavailability of Paramethasone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The bioavailability of Aldosterone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The bioavailability of Fluprednidene can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The bioavailability of Fluocortolone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The bioavailability of Fluprednisolone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The bioavailability of Meprednisone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The bioavailability of Dexamethasone isonicotinate can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The bioavailability of Melengestrol can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The bioavailability of Clobetasol can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The bioavailability of Deflazacort can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The bioavailability of Cortivazol can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The bioavailability of Prednylidene can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The bioavailability of Fluocortin can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The bioavailability of Fluperolone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The bioavailability of Formocortal can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The bioavailability of Halometasone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The bioavailability of Cloprednol can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The bioavailability of Fluclorolone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The bioavailability of Fluticasone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The bioavailability of Hydrocortisone aceponate can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The bioavailability of Hydrocortisone cypionate can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The bioavailability of Loteprednol can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The bioavailability of Prednisolone phosphate can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The bioavailability of Prednisolone hemisuccinate can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The bioavailability of Fluprednidene acetate can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The bioavailability of Methylprednisolone aceponate can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The bioavailability of Prednisone acetate can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The bioavailability of Clocortolone acetate can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The bioavailability of Melengestrol acetate can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The bioavailability of Betamethasone phosphate can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The bioavailability of Cortisone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The serum concentration of Amphetamine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The serum concentration of Phentermine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The serum concentration of Pseudoephedrine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The serum concentration of Benzphetamine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The serum concentration of Diethylpropion can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The serum concentration of Lisdexamfetamine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The serum concentration of Mephentermine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The serum concentration of MMDA can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The serum concentration of Midomafetamine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>The serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The serum concentration of Tenamfetamine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>The serum concentration of Chlorphentermine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01566</drugbank-id>
      <name>Methylenedioxyethamphetamine</name>
      <description>The serum concentration of Methylenedioxyethamphetamine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The serum concentration of Dextroamphetamine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The serum concentration of Metamfetamine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>The serum concentration of Iofetamine I-123 can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The serum concentration of Ritobegron can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>The serum concentration of Mephedrone can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The serum concentration of Methoxyphenamine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>The serum concentration of Gepefrine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09139</drugbank-id>
      <name>Technetium Tc-99m oxidronate</name>
      <description>The serum concentration of Technetium Tc-99m oxidronate can be increased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Propacetamol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01378</drugbank-id>
      <name>Magnesium cation</name>
      <description>The therapeutic efficacy of Magnesium cation can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01638</drugbank-id>
      <name>Sorbitol</name>
      <description>The therapeutic efficacy of Sorbitol can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The therapeutic efficacy of Magnesium trisilicate can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09413</drugbank-id>
      <name>Monopotassium phosphate</name>
      <description>The therapeutic efficacy of Monopotassium phosphate can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09414</drugbank-id>
      <name>Dipotassium phosphate</name>
      <description>The therapeutic efficacy of Dipotassium phosphate can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09449</drugbank-id>
      <name>Sodium phosphate, monobasic</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09462</drugbank-id>
      <name>Glycerin</name>
      <description>The therapeutic efficacy of Glycerin can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09472</drugbank-id>
      <name>Sodium sulfate</name>
      <description>The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09484</drugbank-id>
      <name>Sodium fluorophosphate</name>
      <description>The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11189</drugbank-id>
      <name>Magnesium glycinate</name>
      <description>The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12942</drugbank-id>
      <name>Lactitol</name>
      <description>The therapeutic efficacy of Lactitol can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13526</drugbank-id>
      <name>Pentaerithrityl</name>
      <description>The therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13707</drugbank-id>
      <name>Sodium tartrate</name>
      <description>The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14482</drugbank-id>
      <name>Sodium ascorbate</name>
      <description>The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14499</drugbank-id>
      <name>Potassium sulfate</name>
      <description>The therapeutic efficacy of Potassium sulfate can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14502</drugbank-id>
      <name>Sodium phosphate, dibasic</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14503</drugbank-id>
      <name>Sodium phosphate, monobasic, unspecified form</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14504</drugbank-id>
      <name>Sodium phosphate, dibasic, unspecified form</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14513</drugbank-id>
      <name>Magnesium</name>
      <description>The therapeutic efficacy of Magnesium can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Voriconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01110</drugbank-id>
      <name>Miconazole</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04794</drugbank-id>
      <name>Bifonazole</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Bifonazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06395</drugbank-id>
      <name>Abafungin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06440</drugbank-id>
      <name>Ravuconazole</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ravuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06636</drugbank-id>
      <name>Isavuconazonium</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Isavuconazonium resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08943</drugbank-id>
      <name>Isoconazole</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Isoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Isavuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12073</drugbank-id>
      <name>Albaconazole</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Albaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13425</drugbank-id>
      <name>Flutrimazole</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Flutrimazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13434</drugbank-id>
      <name>Fenticonazole</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Fenticonazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13684</drugbank-id>
      <name>Omoconazole</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Omoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Mephenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Carbamazepine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Methylphenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Phenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Tipranavir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Saquinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Darunavir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01319</drugbank-id>
      <name>Fosamprenavir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11586</drugbank-id>
      <name>Asunaprevir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00581</drugbank-id>
      <name>Lactulose</name>
      <description>The therapeutic efficacy of Lactulose can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The absorption of Palbociclib can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06701</drugbank-id>
      <name>Dexmethylphenidate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Dexmethylphenidate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The risk or severity of adverse effects can be increased when Aluminium phosphate is combined with Erdafitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Digoxin can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>The serum concentration of Metildigoxin can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The serum concentration of Acetyldigoxin can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00535</drugbank-id>
      <name>Cefdinir</name>
      <description>The therapeutic efficacy of Cefdinir can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>Naproxen can cause a decrease in the absorption of Aluminium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>The bioavailability of Gabapentin can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01112</drugbank-id>
      <name>Cefuroxime</name>
      <description>The serum concentration of Cefuroxime can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09101</drugbank-id>
      <name>Elvitegravir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08872</drugbank-id>
      <name>Gabapentin enacarbil</name>
      <description>The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Aluminium phosphate may decrease the excretion rate of Mecamylamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>Aluminium phosphate may decrease the excretion rate of Memantine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The serum concentration of Sotalol can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>The therapeutic efficacy of Sulpiride can be increased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06783</drugbank-id>
      <name>Prussian blue</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09146</drugbank-id>
      <name>Iron sucrose</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09501</drugbank-id>
      <name>Ferric ammonium citrate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09507</drugbank-id>
      <name>Ferumoxsil</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09508</drugbank-id>
      <name>Ferumoxides</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11171</drugbank-id>
      <name>Ferric sulfate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11210</drugbank-id>
      <name>Ferrous bisglycinate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11417</drugbank-id>
      <name>Gleptoferron</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12208</drugbank-id>
      <name>Iron isomaltoside 1000</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12821</drugbank-id>
      <name>Perflubutane</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13257</drugbank-id>
      <name>Ferrous sulfate anhydrous</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13381</drugbank-id>
      <name>Sodium feredetate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13423</drugbank-id>
      <name>Ferric hydroxide</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13569</drugbank-id>
      <name>Ferrous chloride</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13949</drugbank-id>
      <name>Ferric cation</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14488</drugbank-id>
      <name>Ferrous gluconate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14489</drugbank-id>
      <name>Ferrous succinate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14491</drugbank-id>
      <name>Ferrous fumarate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14520</drugbank-id>
      <name>Tetraferric tricitrate decahydrate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14695</drugbank-id>
      <name>Ferric oxyhydroxide</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferric oxyhydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00893</drugbank-id>
      <name>Iron Dextran</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01592</drugbank-id>
      <name>Iron</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09147</drugbank-id>
      <name>Ferric pyrophosphate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01071</drugbank-id>
      <name>Mequitazine</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Mequitazine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>aluminium(3+) phosphate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>aluminium phosphate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>121.9529</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>121.934958441</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[Al+3].[O-]P([O-])([O-])=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>AlO4P</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/Al.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+3;/p-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>ILRRQNADMUWWFW-UHFFFAOYSA-K</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>86.25</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>11.29</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>4.93</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>1.8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>58204</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Aluminium_phosphate</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL3833315</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000510</id>
      <name>Serotransferrin</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A12658</ref-id>
            <pubmed-id>11327511</pubmed-id>
            <citation>Nolte E, Beck E, Winklhofer C, Steinhausen C: Compartmental model for aluminium biokinetics. Hum Exp Toxicol. 2001 Feb;20(2):111-7.</citation>
          </article>
          <article>
            <ref-id>A12659</ref-id>
            <pubmed-id>16139893</pubmed-id>
            <citation>Nagaoka MH, Maitani T: Binding affinity of aluminium to human serum transferrin and effects of carbohydrate chain modification as studied by HPLC/high-resolution ICP-MS--speciation of aluminium in human serum. J Inorg Biochem. 2005 Sep;99(9):1887-94.</citation>
          </article>
          <article>
            <ref-id>A12660</ref-id>
            <pubmed-id>16301797</pubmed-id>
            <citation>Mizutani K, Mikami B, Aibara S, Hirose M: Structure of aluminium-bound ovotransferrin at 2.15 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1636-42. Epub 2005 Nov 19.</citation>
          </article>
          <article>
            <ref-id>A12661</ref-id>
            <pubmed-id>17629565</pubmed-id>
            <citation>Beardmore J, Rugg G, Exley C: A systems biology approach to the blood-aluminium problem: the application and testing of a computational model. J Inorg Biochem. 2007 Sep;101(9):1187-91. Epub 2007 Jun 12.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02787" source="Swiss-Prot">
        <name>Serotransferrin</name>
        <general-function>Transferrin receptor binding</general-function>
        <specific-function>Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation.</specific-function>
        <gene-name>TF</gene-name>
        <locus>3q22.1</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi>7.13</theoretical-pi>
        <molecular-weight>77063.195</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11740</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>TF</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M12530</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>339453</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02787</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TRFE_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Beta-1 metal-binding globulin</synonym>
          <synonym>Siderophilin</synonym>
          <synonym>Transferrin</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037031|Serotransferrin
MRLAVGALLVCAVLGLCLAVPDKTVRWCAVSEHEATKCQSFRDHMKSVIPSDGPSVACVK
KASYLDCIRAIAANEADAVTLDAGLVYDAYLAPNNLKPVVAEFYGSKEDPQTFYYAVAVV
KKDSGFQMNQLRGKKSCHTGLGRSAGWNIPIGLLYCDLPEPRKPLEKAVANFFSGSCAPC
ADGTDFPQLCQLCPGCGCSTLNQYFGYSGAFKCLKDGAGDVAFVKHSTIFENLANKADRD
QYELLCLDNTRKPVDEYKDCHLAQVPSHTVVARSMGGKEDLIWELLNQAQEHFGKDKSKE
FQLFSSPHGKDLLFKDSAHGFLKVPPRMDAKMYLGYEYVTAIRNLREGTCPEAPTDECKP
VKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKIMNGEADAMSLDGGFVYIAGK
CGLVPVLAENYNKSDNCEDTPEAGYFAIAVVKKSASDLTWDNLKGKKSCHTAVGRTAGWN
IPMGLLYNKINHCRFDEFFSEGCAPGSKKDSSLCKLCMGSGLNLCEPNNKEGYYGYTGAF
RCLVEKGDVAFVKHQTVPQNTGGKNPDPWAKNLNEKDYELLCLDGTRKPVEEYANCHLAR
APNHAVVTRKDKEACVHKILRQQQHLFGSNVTDCSGNFCLFRSETKDLLFRDDTVCLAKL
HDRNTYEKYLGEEYVKAVGNLRKCSTSSLLEACTFRRP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021268|Serotransferrin (TF)
ATGAGGCTCGCCGTGGGAGCCCTGCTGGTCTGCGCCGTCCTGGGGCTGTGTCTGGCTGTC
CCTGATAAAACTGTGAGATGGTGTGCAGTGTCGGAGCATGAGGCCACTAAGTGCCAGAGT
TTCCGCGACCATATGAAAAGCGTCATTCCATCCGATGGTCCCAGTGTTGCTTGTGTGAAG
AAAGCCTCCTACCTTGATTGCATCAGGGCCATTGCGGCAAACGAAGCGGATGCTGTGACA
CTGGATGCAGGTTTGGTGTATGATGCTTACCTGGCTCCCAATAACCTGAAGCCTGTGGTG
GCAGAGTTCTATGGGTCAAAAGAGGATCCACAGACTTTCTATTATGCTGTTGCTGTGGTG
AAGAAGGATAGTGGCTTCCAGATGAACCAGCTTCGAGGCAAGAAGTCCTGCCACACGGGT
CTAGGCAGGTCCGCTGGGTGGAACATCCCCATAGGCTTACTTTACTGTGACTTACCTGAG
CCACGTAAACCTCTTGAGAAAGCAGTGGCCAATTTCTTCTCGGGCAGCTGTGCCCCTTGT
GCGGATGGGACGGACTTCCCCCAGCTGTGTCAACTGTGTCCAGGGTGTGGCTGCTCCACC
CTTAACCAATACTTCGGCTACTCGGGAGCCTTCAAGTGTCTGAAGGATGGTGCTGGGGAT
GTGGCCTTTGTCAAGCACTCGACTATATTTGAGAACTTGGCAAACAAGGCTGACAGGGAC
CAGTATGAGCTGCTTTGCCTGGACAACACCCGGAAGCCGGTAGATGAATACAAGGACTGC
CACTTGGCCCAGGTCCCTTCTCATACCGTCGTGGCCCGAAGTATGGGCGGCAAGGAGGAC
TTGATCTGGGAGCTTCTCAACCAGGCCCAGGAACATTTTGGCAAAGACAAATCAAAAGAA
TTCCAACTATTCAGCTCTCCTCATGGGAAGGACCTGCTGTTTAAGGACTCTGCCCACGGG
TTTTTAAAAGTCCCCCCCAGGATGGATGCCAAGATGTACCTGGGCTATGAGTATGTCACT
GCCATCCGGAATCTACGGGAAGGCACATGCCCAGAAGCCCCAACAGATGAATGCAAGCCT
GTGAAGTGGTGTGCGCTGAGCCACCACGAGAGGCTCAAGTGTGATGAGTGGAGTGTTAAC
AGTGTAGGGAAAATAGAGTGTGTATCAGCAGAGACCACCGAAGACTGCATCGCCAAGATC
ATGAATGGAGAAGCTGATGCCATGAGCTTGGATGGAGGGTTTGTCTACATAGCGGGCAAG
TGTGGTCTGGTGCCTGTCTTGGCAGAAAACTACAATAAGAGCGATAATTGTGAGGATACA
CCAGAGGCAGGGTATTTTGCTGTAGCAGTGGTGAAGAAATCAGCTTCTGACCTCACCTGG
GACAATCTGAAAGGCAAGAAGTCCTGCCATACGGCAGTTGGCAGAACCGCTGGCTGGAAC
ATCCCCATGGGCCTGCTCTACAATAAGATCAACCACTGCAGATTTGATGAATTTTTCAGT
GAAGGTTGTGCCCCTGGGTCTAAGAAAGACTCCAGTCTCTGTAAGCTGTGTATGGGCTCA
GGCCTAAACCTGTGTGAACCCAACAACAAAGAGGGATACTACGGCTACACAGGCGCTTTC
AGGTGTCTGGTTGAGAAGGGAGATGTGGCCTTTGTGAAACACCAGACTGTCCCACAGAAC
ACTGGGGGAAAAAACCCTGATCCATGGGCTAAGAATCTGAATGAAAAAGACTATGAGTTG
CTGTGCCTTGATGGTACCAGGAAACCTGTGGAGGAGTATGCGAACTGCCACCTGGCCAGA
GCCCCGAATCACGCTGTGGTCACACGGAAAGATAAGGAAGCTTGCGTCCACAAGATATTA
CGTCAACAGCAGCACCTATTTGGAAGCAACGTAACTGACTGCTCGGGCAACTTTTGTTTG
TTCCGGTCGGAAACCAAGGACCTTCTGTTCAGAGATGACACAGTATGTTTGGCCAAACTT
CATGACAGAAACACATATGAAAAATACTTAGGAGAAGAATATGTCAAGGCTGTTGGTAAC
CTGAGAAAATGCTCCACCTCATCACTCCTGGAAGCCTGCACTTTCCGTAGACCTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00405</identifier>
            <name>Transferrin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basal part of cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basal plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>coated pit</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic membrane-bounded vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>early endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extrinsic component of external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>HFE-transferrin receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>late endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>recycling endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ferric iron binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ferric iron transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ferrous iron binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transferrin receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to iron ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ferrous iron import into cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein stability</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transferrin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000732</id>
      <name>Sodium/potassium-transporting ATPase subunit alpha-1</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A12662</ref-id>
            <pubmed-id>11509182</pubmed-id>
            <citation>Menz RI, Walker JE, Leslie AG: Structure of bovine mitochondrial F(1)-ATPase with nucleotide bound to all three catalytic sites: implications for the mechanism of rotary catalysis. Cell. 2001 Aug 10;106(3):331-41.</citation>
          </article>
          <article>
            <ref-id>A12663</ref-id>
            <pubmed-id>14507470</pubmed-id>
            <citation>Silva VS, Goncalves PP: The inhibitory effect of aluminium on the (Na+/K+)ATPase activity of rat brain cortex synaptosomes. J Inorg Biochem. 2003 Sep 15;97(1):143-50.</citation>
          </article>
          <article>
            <ref-id>A12664</ref-id>
            <pubmed-id>15111247</pubmed-id>
            <citation>Amador FC, Santos MS, Oliveira CR: Lipid peroxidation and aluminium effects on the cholinergic system in nerve terminals. Neurotox Res. 2001 Jul;3(3):223-33.</citation>
          </article>
          <article>
            <ref-id>A12665</ref-id>
            <pubmed-id>15254985</pubmed-id>
            <citation>Kohila T, Parkkonen E, Tahti H: Evaluation of the effects of aluminium, ethanol and their combination on rat brain synaptosomal integral proteins in vitro and after 90-day oral exposure. Arch Toxicol. 2004 May;78(5):276-82.</citation>
          </article>
          <article>
            <ref-id>A12666</ref-id>
            <pubmed-id>15651920</pubmed-id>
            <citation>Kohila T, Tahti H: Effects of aluminium and lead on ATPase activity of knockout +/- mouse cerebral synaptosomes in vitro. Altern Lab Anim. 2004 Oct;32(4):361-7.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05023" source="Swiss-Prot">
        <name>Sodium/potassium-transporting ATPase subunit alpha-1</name>
        <general-function>Steroid hormone binding</general-function>
        <specific-function>This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.</specific-function>
        <gene-name>ATP1A1</gene-name>
        <locus>1p21</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>88-108
132-152
289-308
321-338
773-792
803-823
844-866
919-938
952-970
986-1006</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.15</theoretical-pi>
        <molecular-weight>112895.01</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:799</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ATP1A1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D00099</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>219942</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05023</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>AT1A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.6.3.9</synonym>
          <synonym>Na(+)/K(+) ATPase alpha-1 subunit</synonym>
          <synonym>Sodium pump subunit alpha-1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001460|Sodium/potassium-transporting ATPase subunit alpha-1
MGKGVGRDKYEPAAVSEQGDKKGKKGKKDRDMDELKKEVSMDDHKLSLDELHRKYGTDLS
RGLTSARAAEILARDGPNALTPPPTTPEWIKFCRQLFGGFSMLLWIGAILCFLAYSIQAA
TEEEPQNDNLYLGVVLSAVVIITGCFSYYQEAKSSKIMESFKNMVPQQALVIRNGEKMSI
NAEEVVVGDLVEVKGGDRIPADLRIISANGCKVDNSSLTGESEPQTRSPDFTNENPLETR
NIAFFSTNCVEGTARGIVVYTGDRTVMGRIATLASGLEGGQTPIAAEIEHFIHIITGVAV
FLGVSFFILSLILEYTWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKN
LEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTENQSGVSFDKTSATWLA
LSRIAGLCNRAVFQANQENLPILKRAVAGDASESALLKCIELCCGSVKEMRERYAKIVEI
PFNSTNKYQLSIHKNPNTSEPQHLLVMKGAPERILDRCSSILLHGKEQPLDEELKDAFQN
AYLELGGLGERVLGFCHLFLPDEQFPEGFQFDTDDVNFPIDNLCFVGLISMIDPPRAAVP
DAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVSQVNPRDA
KACVVHGSDLKDMTSEQLDDILKYHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVN
DSPALKKADIGVAMGIAGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTL
TSNIPEITPFLIFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEQAESDIMKRQPRNPK
TDKLVNERLISMAYGQIGMIQALGGFFTYFVILAENGFLPIHLLGLRVDWDDRWINDVED
SYGQQWTYEQRKIVEFTCHTAFFVSIVVVQWADLVICKTRRNSVFQQGMKNKILIFGLFE
ETALAAFLSYCPGMGVALRMYPLKPTWWFCAFPYSLLIFVYDEVRKLIIRRRPGGWVEKE
TYY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016191|Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1)
ATGGGGAAGGGGGTTGGACGTGATAAGTATGAGCCTGCAGCTGTTTCAGAACAAGGTGAT
AAAAAGGGCAAAAAGGGCAAAAAAGACAGGGACATGGATGAACTGAAGAAAGAAGTTTCT
ATGGATGATCATAAACTTAGCCTTGATGAACTTCATCGTAAATATGGAACAGACTTGAGC
CGGGGATTAACATCTGCTCGTGCAGCTGAGATCCTGGCGCGAGATGGTCCCAACGCCCTC
ACTCCCCCTCCCACTACTCCTGAATGGATCAAGTTTTGTCGGCAGCTCTTTGGGGGGTTC
TCAATGTTACTGTGGATTGGAGCGATTCTTTGTTTCTTGGCTTATAGCATCCAAGCTGCT
ACAGAAGAGGAACCTCAAAACGATAATCTGTACCTGGGTGTGGTGCTATCAGCCGTTGTA
ATCATAACTGGTTGCTTCTCCTACTATCAAGAAGCTAAAAGTTCAAAGATCATGGAATCC
TTCAAAAACATGGTCCCTCAGCAAGCCCTTGTGATTCGAAATGGTGAGAAAATGAGCATA
AATGCGGAGGAAGTTGTGGTTGGGGATCTGGTGGAAGTAAAAGGAGGAGACCGAATTCCT
GCTGACCTCAGAATCATATCTGCAAATGGCTGCAAGGTGGATAACTCCTCGCTCACTGGT
GAATCAGAACCCCAGACTAGGTCTCCAGATTTCACAAATGAAAACCCCCTGGAGACGAGG
AACATTGCCTTCTTTTCAACCAATTGTGTTGAAGGCACCGCACGTGGTATTGTTGTCTAC
ACTGGGGATCGCACTGTGATGGGAAGAATTGCCACACTTGCTTCTGGGCTGGAAGGAGGC
CAGACCCCCATTGCTGCAGAAATTGAACATTTTATCCACATCATCACGGGTGTGGCTGTG
TTCCTGGGTGTGTCTTTCTTCATCCTTTCTCTCATCCTTGAGTACACCTGGCTTGAGGCT
GTCATCTTCCTCATCGGTATCATCGTAGCCAATGTGCCGGAAGGTTTGCTGGCCACTGTC
ACGGTCTGTCTGACACTTACTGCCAAACGCATGGCAAGGAAAAACTGCTTAGTGAAGAAC
TTAGAAGCTGTGGAGACCTTGGGGTCCACGTCCACCATCTGCTCTGATAAAACTGGAACT
CTGACTCAGAACCGGATGACAGTGGCCCACATGTGGTTTGACAATCAAATCCATGAAGCT
GATACGACAGAGAATCAGAGTGGTGTCTCTTTTGACAAGACTTCAGCTACCTGGCTTGCT
CTGTCCAGAATTGCAGGTCTTTGTAACAGGGCAGTGTTTCAGGCTAACCAGGAAAACCTA
CCTATTCTTAAGCGGGCAGTTGCAGGAGATGCCTCTGAGTCAGCACTCTTAAAGTGCATA
GAGCTGTGCTGTGGTTCCGTGAAGGAGATGAGAGAAAGATACGCCAAAATCGTCGAGATA
CCCTTCAACTCCACCAACAAGTACCAGTTGTCTATTCATAAGAACCCCAACACATCGGAG
CCCCAACACCTGTTGGTGATGAAGGGCGCCCCAGAAAGGATCCTAGACCGTTGCAGCTCT
ATCCTCCTCCACGGCAAGGAGCAGCCCCTGGATGAGGAGCTGAAAGACGCCTTTCAGAAC
GCCTATTTGGAGCTGGGGGGCCTCGGAGAACGAGTCCTAGGTTTCTGCCACCTCTTTCTG
CCAGATGAACAGTTTCCTGAAGGGTTCCAGTTTGACACTGACGATGTGAATTTCCCTATC
GATAATCTGTGCTTTGTTGGGCTCATCTCCATGATTGACCCTCCACGGGCGGCCGTTCCT
GATGCCGTGGGCAAATGTCGAAGTGCTGGAATTAAGGTCATCATGGTCACAGGAGACCAT
CCAATCACAGCTAAAGCTATTGCCAAAGGTGTGGGCATCATCTCAGAAGGCAATGAGACC
GTGGAAGACATTGCTGCCCGCCTCAACATCCCAGTCAGCCAGGTGAACCCCAGGGATGCC
AAGGCCTGCGTAGTACACGGCAGTGATCTAAAGGACATGACCTCCGAGCAGCTGGATGAC
ATTTTGAAGTACCACACTGAGATAGTGTTTGCCAGGACCTCCCCTCAGCAGAAGCTCATC
ATTGTGGAAGGCTGCCAAAGACAGGGTGCTATCGTGGCTGTGACTGGTGACGGTGTGAAT
GACTCTCCAGCTTTGAAGAAAGCAGACATTGGGGTTGCTATGGGGATTGCTGGCTCAGAT
GTGTCCAAGCAAGCTGCTGACATGATTCTTCTGGATGACAACTTTGCCTCAATTGTGACT
GGAGTAGAGGAAGGTCGTCTGATCTTTGATAACTTGAAGAAATCCATTGCTTATACCTTA
ACCAGTAACATTCCCGAGATCACCCCGTTCCTGATATTTATTATTGCAAACATTCCACTA
CCACTGGGGACTGTCACCATCCTCTGCATTGACTTGGGCACTGACATGGTTCCTGCCATC
TCCCTGGCTTATGAGCAGGCTGAGAGTGACATCATGAAGAGACAGCCCAGAAATCCCAAA
ACAGACAAACTTGTGAATGAGCGGCTGATCAGCATGGCCTATGGGCAGATTGGAATGATC
CAGGCCCTGGGAGGCTTCTTTACTTACTTTGTGATTCTGGCTGAGAACGGCTTCCTCCCA
ATTCACCTGTTGGGCCTCCGAGTGGACTGGGATGACCGCTGGATCAACGATGTGGAAGAC
AGCTACGGGCAGCAGTGGACCTATGAGCAGAGGAAAATCGTGGAGTTCACCTGCCACACA
GCCTTCTTCGTCAGTATCGTGGTGGTGCAGTGGGCCGACTTGGTCATCTGTAAGACCAGG
AGGAATTCGGTCTTCCAGCAGGGGATGAAGAACAAGATCTTGATATTTGGCCTCTTTGAA
GAGACAGCCCTGGCTGCTTTCCTTTCCTACTGCCCTGGAATGGGTGTTGCTCTTAGGATG
TATCCCCTCAAACCTACCTGGTGGTTCTGTGCCTTCCCCTACTCTCTTCTCATCTTCGTA
TATGACGAAGTCAGAAAACTCATCATCAGGCGACGCCCTGGCGGCTGGGTGGAGAAGGAA
ACCTACTATTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00689</identifier>
            <name>Cation_ATPase_C</name>
          </pfam>
          <pfam>
            <identifier>PF00690</identifier>
            <name>Cation_ATPase_N</name>
          </pfam>
          <pfam>
            <identifier>PF00122</identifier>
            <name>E1-E2_ATPase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intercalated disc</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>melanosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myelin sheath</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcolemma</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sodium</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>T-tubule</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ADP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chaperone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>potassium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ATP hydrolysis coupled proton transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell communication by electrical coupling involved in cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular potassium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to mechanical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to steroid hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular sodium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>establishment or maintenance of transmembrane electrochemical gradient</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane hyperpolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane repolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane repolarization during cardiac muscle cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glucocorticoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of heart contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of heart contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of striated muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>potassium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>potassium ion import across plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein dephosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cardiac muscle cell contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sodium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of the force of heart contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>relaxation of cardiac muscle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glycoside</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion export from cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0001091</id>
      <name>Kallikrein-1</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A19929</ref-id>
            <pubmed-id>15558947</pubmed-id>
            <citation>De Sousa MO, Santoro MM, De Souza Figueiredo AF: The effect of cations on the amidase activity of human tissue kallikrein: 1-linear competitive inhibition by sodium, potassium, calcium and magnesium. 2-linear mixed inhibition by aluminium. J Enzyme Inhib Med Chem. 2004 Aug;19(4):317-25.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P06870" source="Swiss-Prot">
        <name>Kallikrein-1</name>
        <general-function>Serine-type endopeptidase activity</general-function>
        <specific-function>Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.</specific-function>
        <gene-name>KLK1</gene-name>
        <locus>19q13.3</locus>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>4.39</theoretical-pi>
        <molecular-weight>28889.425</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6357</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>KLK1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M25629</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>186653</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2865</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P06870</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>KLK1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.21.35</synonym>
          <synonym>Kidney/pancreas/salivary gland kallikrein</synonym>
          <synonym>Tissue kallikrein</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037122|Kallikrein-1
MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWV
LTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHD
LMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKIL
PNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNK
PSVAVRVLSYVKWIEDTIAENS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010764|Kallikrein-1 (KLK1)
ATGTGGTTCCTGGTTCTGTGCCTCGCCCTGTCCCTGGGGGGGACTGGTGCTGCGCCCCCG
ATTCAGTCCCGGATTGTGGGAGGCTGGGAGTGTGAGCAGCATTCCCAGCCCTGGCAGGCG
GCTCTGTACCATTTCAGCACTTTCCAGTGTGGGGGCATCCTGGTGCACCGCCAGTGGGTG
CTCACAGCTGCTCATTGCATCAGCGACAATTACCAGCTCTGGCTGGGTCGCCACAACTTG
TTTGACGACGAAAACACAGCCCAGTTTGTTCATGTCAGTGAGAGCTTCCCACACCCTGGC
TTCAACATGAGCCTCCTGGAGAACCACACCCGCCAAGCAGACGAGGACTACAGCCACGAC
CTCATGCTGCTCCGCCTGACAGAGCCTGCTGATACCATCACAGATGCTGTGAAGGTCGTG
GAGTTGCCCACCGAGGAACCCGAAGTGGGGAGCACCTGTTTGGCTTCCGGCTGGGGCAGC
ATCGAACCAGAGAATTTCTCATTTCCAGATGATCTCCAGTGTGTGGACCTCAAAATCCTG
CCTAATGATGAGTGCAAAAAAGCCCACGTCCAGAAGGTGACAGACTTCATGCTGTGTGTC
GGACACCTGGAAGGTGGCAAAGACACCTGTGTGGGTGATTCAGGGGGCCCGCTGATGTGT
GATGGTGTGCTCCAAGGTGTCACATCATGGGGCTACGTCCCTTGTGGCACCCCCAATAAG
CCTTCTGTCGCCGTCAGAGTGCTGTCTTATGTGAAGTGGATCGAGGACACCATAGCGGAG
AACTCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00089</identifier>
            <name>Trypsin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acute inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>zymogen activation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0003392</id>
      <name>Amyloid beta A4 protein</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A20024</ref-id>
            <pubmed-id>16942756</pubmed-id>
            <citation>Banks WA, Niehoff ML, Drago D, Zatta P: Aluminum complexing enhances amyloid beta protein penetration of blood-brain barrier. Brain Res. 2006 Oct 20;1116(1):215-21. Epub 2006 Aug 30.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05067" source="Swiss-Prot">
        <name>Amyloid beta A4 protein</name>
        <general-function>Transition metal ion binding</general-function>
        <specific-function>Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Beta-amyloid 42 is a more effective reductant than beta-amyloid 40. Beta-amyloid peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Beta-APP42 may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Also binds GPC1 in lipid rafts.Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain.The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6).</specific-function>
        <gene-name>APP</gene-name>
        <locus/>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>700-723</transmembrane-regions>
        <signal-regions>1-17</signal-regions>
        <theoretical-pi>4.45</theoretical-pi>
        <molecular-weight>86942.715</molecular-weight>
        <chromosome-location>21</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:620</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>APP</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X06989</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05067</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>A4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>A4</synonym>
          <synonym>ABPP</synonym>
          <synonym>AD1</synonym>
          <synonym>Alzheimer disease amyloid protein</synonym>
          <synonym>APP</synonym>
          <synonym>APPI</synonym>
          <synonym>Cerebral vascular amyloid peptide</synonym>
          <synonym>CVAP</synonym>
          <synonym>PN-II</synonym>
          <synonym>PreA4</synonym>
          <synonym>Protease nexin-II</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006619|Amyloid beta A4 protein
MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTK
TCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVG
EFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFR
GVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEE
EADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPC
RAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARD
PVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQA
KNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITAL
QAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYER
MNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTET
KTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTN
IKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITL
VMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019416|Amyloid beta A4 protein (APP)
ATGCTGCCCGGTTTGGCACTGCTCCTGCTGGCCGCCTGGACGGCTCGGGCGCTGGAGGTA
CCCACTGATGGTAATGCTGGCCTGCTGGCTGAACCCCAGATTGCCATGTTCTGTGGCAGA
CTGAACATGCACATGAATGTCCAGAATGGGAAGTGGGATTCAGATCCATCAGGGACCAAA
ACCTGCATTGATACCAAGGAAGGCATCCTGCAGTATTGCCAAGAAGTCTACCCTGAACTG
CAGATCACCAATGTGGTAGAAGCCAACCAACCAGTGACCATCCAGAACTGGTGCAAGCGG
GGCCGCAAGCAGTGCAAGACCCATCCCCACTTTGTGATTCCCTACCGCTGCTTAGTTGGT
GAGTTTGTAAGTGATGCCCTTCTCGTTCCTGACAAGTGCAAATTCTTACACCAGGAGAGG
ATGGATGTTTGCGAAACTCATCTTCACTGGCACACCGTCGCCAAAGAGACATGCAGTGAG
AAGAGTACCAACTTGCATGACTACGGCATGTTGCTGCCCTGCGGAATTGACAAGTTCCGA
GGGGTAGAGTTTGTGTGTTGCCCACTGGCTGAAGAAAGTGACAATGTGGATTCTGCTGAT
GCGGAGGAGGATGACTCGGATGTCTGGTGGGGCGGAGCAGACACAGACTATGCAGATGGG
AGTGAAGACAAAGTAGTAGAAGTAGCAGAGGAGGAAGAAGTGGCTGAGGTGGAAGAAGAA
GAAGCCGATGATGACGAGGACGATGAGGATGGTGATGAGGTAGAGGAAGAGGCTGAGGAA
CCCTACGAAGAAGCCACAGAGAGAACCACCAGCATTGCCACCACCACCACCACCACCACA
GAGTCTGTGGAAGAGGTGGTTCGAGAGGTGTGCTCTGAACAAGCCGAGACGGGGCCGTGC
CGAGCAATGATCTCCCGCTGGTACTTTGATGTGACTGAAGGGAAGTGTGCCCCATTCTTT
TACGGCGGATGTGGCGGCAACCGGAACAACTTTGACACAGAAGAGTACTGCATGGCCGTG
TGTGGCAGCGCCATGTCCCAAAGTTTACTCAAGACTACCCAGGAACCTCTTGCCCGAGAT
CCTGTTAAACTTCCTACAACAGCAGCCAGTACCCCTGATGCCGTTGACAAGTATCTCGAG
ACACCTGGGGATGAGAATGAACATGCCCATTTCCAGAAAGCCAAAGAGAGGCTTGAGGCC
AAGCACCGAGAGAGAATGTCCCAGGTCATGAGAGAATGGGAAGAGGCAGAACGTCAAGCA
AAGAACTTGCCTAAAGCTGATAAGAAGGCAGTTATCCAGCATTTCCAGGAGAAAGTGGAA
TCTTTGGAACAGGAAGCAGCCAACGAGAGACAGCAGCTGGTGGAGACACACATGGCCAGA
GTGGAAGCCATGCTCAATGACCGCCGCCGCCTGGCCCTGGAGAACTACATCACCGCTCTG
CAGGCTGTTCCTCCTCGGCCTCGTCACGTGTTCAATATGCTAAAGAAGTATGTCCGCGCA
GAACAGAAGGACAGACAGCACACCCTAAAGCATTTCGAGCATGTGCGCATGGTGGATCCC
AAGAAAGCCGCTCAGATCCGGTCCCAGGTTATGACACACCTCCGTGTGATTTATGAGCGC
ATGAATCAGTCTCTCTCCCTGCTCTACAACGTGCCTGCAGTGGCCGAGGAGATTCAGGAT
GAAGTTGATGAGCTGCTTCAGAAAGAGCAAAACTATTCAGATGACGTCTTGGCCAACATG
ATTAGTGAACCAAGGATCAGTTACGGAAACGATGCTCTCATGCCATCTTTGACCGAAACG
AAAACCACCGTGGAGCTCCTTCCCGTGAATGGAGAGTTCAGCCTGGACGATCTCCAGCCG
TGGCATTCTTTTGGGGCTGACTCTGTGCCAGCCAACACAGAAAACGAAGTTGAGCCTGTT
GATGCCCGCCCTGCTGCCGACCGAGGACTGACCACTCGACCAGGTTCTGGGTTGACAAAT
ATCAAGACGGAGGAGATCTCTGAAGTGAAGATGGATGCAGAATTCCGACATGACTCAGGA
TATGAAGTTCATCATCAAAAATTGGTGTTCTTTGCAGAAGATGTGGGTTCAAACAAAGGT
GCAATCATTGGACTCATGGTGGGCGGTGTTGTCATAGCGACAGTGATCGTCATCACCTTG
GTGATGCTGAAGAAGAAACAGTACACATCCATTCATCATGGTGTGGTGGAGGTTGACGCC
GCTGTCACCCCAGAGGAGCGCCACCTGTCCAAGATGCAGCAGAACGGCTACGAAAATCCA
ACCTACAAGTTCTTTGAGCAGATGCAGAACTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00014</identifier>
            <name>Kunitz_BPTI</name>
          </pfam>
          <pfam>
            <identifier>PF02177</identifier>
            <name>APP_N</name>
          </pfam>
          <pfam>
            <identifier>PF03494</identifier>
            <name>Beta-APP</name>
          </pfam>
          <pfam>
            <identifier>PF10515</identifier>
            <name>APP_amyloid</name>
          </pfam>
          <pfam>
            <identifier>PF12924</identifier>
            <name>APP_Cu_bd</name>
          </pfam>
          <pfam>
            <identifier>PF12925</identifier>
            <name>APP_E2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>coated pit</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic shaft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane raft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>terminal bouton</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>trans-Golgi network membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heparin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptidase activator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>PTB domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transition metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>antibacterial humoral response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>antifungal humoral response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon cargo transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon midline choice point recognition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axonogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular copper ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>collateral sprouting in absence of injury</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to Gram-negative bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to Gram-positive bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dendrite development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ionotropic glutamate receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mating behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mRNA polyadenylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron projection development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Notch signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-Golgi vesicle-mediated transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of epidermal growth factor-activated receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synapse structure or activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of translation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to yeast</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers>
    <carrier position="3">
      <id>BE0000530</id>
      <name>Serum albumin</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A19881</ref-id>
            <pubmed-id>12921780</pubmed-id>
            <citation>Zatta P, Dalla Via L, Di Noto V: Binding studies on aluminum(III)-albumin interaction. Arch Biochem Biophys. 2003 Sep 1;417(1):59-64.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02768" source="Swiss-Prot">
        <name>Serum albumin</name>
        <general-function>Toxic substance binding</general-function>
        <specific-function>Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.</specific-function>
        <gene-name>ALB</gene-name>
        <locus>4q11-q13</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>6.21</theoretical-pi>
        <molecular-weight>69365.94</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:399</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ALB</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>V00494</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>28590</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02768</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ALBU_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Serum albumin precursor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001058|Serum albumin
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
AASQAALGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010372|Serum albumin (ALB)
ATGAAGTGGGTAACCTTTATTTCCCTTCTTTTTCTCTTTAGCTCGGCTTATTCCAGGGGT
GTGTTTCGTCGAGATGCACACAAGAGTGAGGTTGCTCATCGGTTTAAAGATTTGGGAGAA
GAAAATTTCAAAGCCTTGGTGTTGATTGCCTTTGCTCAGTATCTTCAGCAGTGTCCATTT
GAAGATCATGTAAAATTAGTGAATGAAGTAACTGAATTTGCAAAAACATGTGTTGCTGAT
GAGTCAGCTGAAAATTGTGACAAATCACTTCATACCCTTTTTGGAGACAAATTATGCACA
GTTGCAACTCTTCGTGAAACCTATGGTGAAATGGCTGACTGCTGTGCAAAACAAGAACCT
GAGAGAAATGAATGCTTCTTGCAACACAAAGATGACAACCCAAACCTCCCCCGATTGGTG
AGACCAGAGGTTGATGTGATGTGCACTGCTTTTCATGACAATGAAGAGACATTTTTGAAA
AAATACTTATATGAAATTGCCAGAAGACATCCTTACTTTTATGCCCCGGAACTCCTTTTC
TTTGCTAAAAGGTATAAAGCTGCTTTTACAGAATGTTGCCAAGCTGCTGATAAAGCTGCC
TGCCTGTTGCCAAAGCTCGATGAACTTCGGGATGAAGGGAAGGCTTCGTCTGCCAAACAG
AGACTCAAGTGTGCCAGTCTCCAAAAATTTGGAGAAAGAGCTTTCAAAGCATGGGCAGTA
GCTCGCCTGAGCCAGAGATTTCCCAAAGCTGAGTTTGCAGAAGTTTCCAAGTTAGTGACA
GATCTTACCAAAGTCCACACGGAATGCTGCCATGGAGATCTGCTTGAATGTGCTGATGAC
AGGGCGGACCTTGCCAAGTATATCTGTGAAAATCAAGATTCGATCTCCAGTAAACTGAAG
GAATGCTGTGAAAAACCTCTGTTGGAAAAATCCCACTGCATTGCCGAAGTGGAAAATGAT
GAGATGCCTGCTGACTTGCCTTCATTAGCTGCTGATTTTGTTGAAAGTAAGGATGTTTGC
AAAAACTATGCTGAGGCAAAGGATGTCTTCCTGGGCATGTTTTTGTATGAATATGCAAGA
AGGCATCCTGATTACTCTGTCGTGCTGCTGCTGAGACTTGCCAAGACATATGAAACCACT
CTAGAGAAGTGCTGTGCCGCTGCAGATCCTCATGAATGCTATGCCAAAGTGTTCGATGAA
TTTAAACCTCTTGTGGAAGAGCCTCAGAATTTAATCAAACAAAATTGTGAGCTTTTTGAG
CAGCTTGGAGAGTACAAATTCCAGAATGCGCTATTAGTTCGTTACACCAAGAAAGTACCC
CAAGTGTCAACTCCAACTCTTGTAGAGGTCTCAAGAAACCTAGGAAAAGTGGGCAGCAAA
TGTTGTAAACATCCTGAAGCAAAAAGAATGCCCTGTGCAGAAGACTATCTATCCGTGGTC
CTGAACCAGTTATGTGTGTTGCATGAGAAAACGCCAGTAAGTGACAGAGTCACCAAATGC
TGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAAACA
TACGTTCCCAAAGAGTTTAATGCTGAAACATTCACCTTCCATGCAGATATATGCACACTT
TCTGAGAAGGAGAGACAAATCAAGAAACAAACTGCACTTGTTGAGCTCGTGAAACACAAG
CCCAAGGCAACAAAAGAGCAACTGAAAGCTGTTATGGATGATTTCGCAGCTTTTGTAGAG
AAGTGCTGCAAGGCTGACGATAAGGAGACCTGCTTTGCCGAGGAGGGTAAAAAACTTGTT
GCTGCAAGTCAAGCTGCCTTAGGCTTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00273</identifier>
            <name>Serum_albumin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myelin sheath</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>antioxidant activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chaperone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>copper ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fatty acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyridoxal phosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>toxic substance binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hemolysis by symbiont of host erythrocytes</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of mitochondrion location</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
  </carriers>
  <transporters/>
</drug>